The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle
Open accessAbstract
Potent sequence selective gene inhibition by siRNA 'targeted' therapeutics promises the ultimate level of specificity, but siRNA therapeutics is hindered by poor intracellular uptake, limited blood stability and non-specific immune stimulation. To address these problems, ligand-targeted, sterically stabilized nanoparticles have been adapted for siRNA. Self-assembling nanoparticles with siRNA were constructed with polyethyleneimine (PEI) that is PEGylated with an Arg-Gly-Asp (RGD) peptide ligand attached at the distal end of the polyethylene glycol (PEG), as a means to target tumor neovasculature expressing integrins and used to deliver siRNA inhibiting vascular endothelial growth factor receptor-2 (VEGF R2) expression and thereby tumor angiogenesis. Cell delivery and activity of PEGylated PEI was found to be siRNA sequence specific and depend on the presence of peptide ligand and could be competed by free peptide. Intravenous administration into tumor-bearing mice gave selective tumor uptake, siRNA sequence-specific inhibition of protein expression within the tumor and inhibition of both tumor angiogenesis and growth rate. The results suggest achievement of two levels of targeting: tumor tissue selective delivery via the nanoparticle ligand and gene pathway selectivity via the siRNA oligonucleotide. This opens the door for better targeted therapeutics with both tissue and gene selectivity, also to improve targeted therapies with less than ideal therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TOLENTINO, M. J., BRUCKER, A. J., FOSNOT, J., YING, G.-S., WU, I.-H., MALIK, G., WAN, S., & REICH, S. J. (2004) · RETINA · doi:10.1097/00006982-200402000-00018 · Cited by 172
RetractedRGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Organ targeting In vivo using phage display peptide libraries
Pasqualini, R., & Ruoslahti, E. (1996) · Nature · doi:10.1038/380364a0 · Cited by 1,221
RNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
Analysis of gene function in somatic mammalian cells using small interfering RNAs
Elbashir, S. (2002) · Methods · doi:10.1016/s1046-2023(02)00023-3 · Cited by 1,095
Tumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
In vivo activity of nuclease-resistant siRNAs
LAYZER, J. M., MCCAFFREY, A. P., TANNER, A. K., HUANG, Z., KAY, M. A., & SULLENGER, B. A. (2004) · RNA · doi:10.1261/rna.5239604 · Cited by 580
Langer, R. (2001) · Science · doi:10.1126/science.1063273 · Cited by 579
Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice
Sørensen, D. R., Leirdal, M., & Sioud, M. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00181-5 · Cited by 464
A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics
Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., & Muramatsu, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2682 · Cited by 378
Brekken, R. A., Overholser, J. P., Stastny, V., Waltenberger, J. L., Minna, J. D., & Thorpe, P. E. (2000) · PubMed · Cited by 331
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen, M. L., Oyen, W. J. G., Dijkgraaf, I., Massuger, L. F. A. G., Frielink, C., Edwards, D. S., Rajopadhye, M., Boonstra, H., Corstens, F. H. M., & Boerman, O. C. (2002) · PubMed · Cited by 331
Zhang, Y., Zhang, Y.-F., Bryant, J., Charles, A., Boado, R. J., & Pardridge, W. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0740 · Cited by 330
Systematic genome-wide screens of gene function
Carpenter, A. E., & Sabatini, D. M. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1248 · Cited by 298
Erbacher, P., Bettinger, T., Belguise-Valladier, P., Zou, S., Coll, J.-L., Behr, J.-P., & Remy, J.-S. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199905/06)1:3<210::aid-jgm30>3.0.co;2-u · Cited by 295
Ogris, M. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00230-x · Cited by 286
O'Neil, K. T., Hoess, R. H., Jackson, S. A., Ramachandran, N. S., Mousa, S. A., & DeGrado, W. F. (1992) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340140411 · Cited by 278
Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A., & Maeda, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00002 · Cited by 278
Zitzmann, S., Ehemann, V., & Schwab, M. (2002) · PubMed · Cited by 265
Filleur, S., Courtin, A., Ait‐Si‐Ali, S., Guglielmi, J., Arnold, C., Harel‐Bellan, A., Clézardin, P., & Cabon, F. (2003) · PubMed · Cited by 253
Nanoparticles for the delivery of genes and drugs to human hepatocytes
Yamada, T., Iwasaki, Y., Tada, H., Iwabuki, H., Chuah, M. K., VandenDriessche, T., Fukuda, H., Kondo, A., Ueda, M., Seno, M., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt843 · Cited by 247
Kim, B., Tang, Q., Biswas, P. S., Xu, J., Schiffelers, R. M., Xie, F. Y., Ansari, A. M., Scaria, P. V., Woodle, M. C., Lu, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63267-1 · Cited by 234
Self-citationOgris, M., Steinlein, P., Carotta, S., Brunner, S., & Wagner, E. (2001) · AAPS PharmSci · doi:10.1208/ps030321 · Cited by 209
An RGD–Oligolysine Peptide: A Prototype Construct for Integrin-Mediated Gene Delivery
Harbottle, R. P., Cooper, R. G., Hart, S. L., Ladhoff, A., McKay, T., Knight, A. M., Wagner, E., Miller, A. D., & Coutelle, C. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.7-1037 · Cited by 189
Hart, S. L., Knight, A. M., Harbottle, R. P., Mistry, A., Hunger, H. D., Cutler, D. F., Williamson, R., & Coutelle, C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99898-4 · Cited by 164
Verbaan, F. J., Oussoren, C., Snel, C. J., Crommelin, D. J. A., Hennink, W. E., & Storm, G. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.475 · Cited by 150
Molecular medicine for the brain: silencing of disease genes with RNA interference
Davidson, B. L., & Paulson, H. L. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00678-7 · Cited by 125
An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier
Suh, W., Han, S., Yu, L., & KIM, S. (2002) · Molecular Therapy · doi:10.1016/s1525-0016(02)90721-5 · Cited by 124
A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis.
Xu, X., Chen, Y., Chen, J., Yang, S., Gao, F., Underhill, C. B., Creswell, K. M., & Zhang, L. (2003) · PubMed · Cited by 72
Targeted nucleic acid delivery into tumors: new avenues for cancer therapy
Wagner, E., Kircheis, R., & Walker, G. F. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.01.003 · Cited by 68
Sterically stabilized polyplex: ligand-mediated activity
Woodle, M. C., Scaria, P. V., Ganesh, S., Subramanian, K., Titmas, R. C., Cheng, C., Yang, J., Pan, Y., Weng, K., Gu, C., et al. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00339-x · Cited by 62
Potential applications of siRNA for pain therapy
Ganju, P., & Hall, J. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.4.531 · Cited by 21
Cited by
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Polymer Therapeutics: Concepts and Applications
Haag, R., & Kratz, F. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502113 · Cited by 1,115
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Metadata
- Authors
- Schiffelers, R. M.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-10-28
- Volume
- 32
- Issue
- 19
- Pages
- e149-e149
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2126630077
- Cited by
- 901
- References
- 35
- FWCI
- 20.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.